Last updated: February 24, 2026
What is NDC 70000-0525?
NDC 70000-0525 is an oral formulation of clozapine, branded as Vraylar (cariprazine). It was approved by the FDA in 2015 for schizophrenia and bipolar disorder. The drug competes in the atypical antipsychotics market, a segment characterized by high R&D costs, regulatory scrutiny, and significant reimbursement considerations.
Market Size and Growth
Global and U.S. Market Overview
- The global antipsychotics market was valued at approximately $7 billion in 2022.
- The U.S. accounts for nearly 70% of the global market, with an estimated value of $4.9 billion in 2022.
- Compound annual growth rate (CAGR) for the segment projected at 3-4% from 2023 to 2028.[1]
Key Market Drivers
- Rising prevalence of schizophrenia (~20 million worldwide).
- Increased diagnosis of bipolar disorder.
- Expanded acceptance of atypical antipsychotics due to improved side effect profiles.
- Off-label uses, including treatment-resistant depression.
Competitive Landscape
Major competitors include:
| Drug |
Brand Name |
Indications |
Estimated 2022 Sales |
Approval Year |
Market Share |
| Risperdal (risperidone) |
Risperdal |
Schizophrenia, bipolar |
$0.9B |
1994 |
18% |
| Abilify (aripiprazole) |
Abilify |
Multiple psychiatric conditions |
$2.4B |
2002 |
49% |
| Latuda (lurasidone) |
Latuda |
Schizophrenia, bipolar |
$1.4B |
2013 |
8% |
| Vraylar (cariprazine) |
Vraylar |
Schizophrenia, bipolar |
$1.2B |
2015 |
5% |
Note: Vraylar's relatively recent market entry limits its current market share but shows strong growth potential.
Price Trends and Projections
Current Pricing (2023)
- The average wholesale acquisition cost (AWAC) per month is approximately $1,200 for a typical dose.
- Insurance reimbursement rates range between $1,000 and $1,300 per month, depending on patient coverage and setting.
Historical Price Movements
- Since FDA approval, Vraylar prices have increased by an average of 4% annually.
- Price stability or slight increases align with inflation and R&D recovery strategies by the manufacturer.
Future Price Projections (2024-2028)
| Year |
Estimated Wholesale Price |
Basis for Estimate |
| 2024 |
$1,250 |
3-4% increase from 2023, aligned with inflation and market expansion |
| 2025 |
$1,290 |
Similar growth assumptions, potentially driven by increased demand |
| 2026 |
$1,330 |
Slight market share gains expected with expanded indications |
| 2027 |
$1,370 |
Price stabilization with mature market penetration |
| 2028 |
$1,410 |
Possible escalation with new formulation options or expanded indications |
Note: Price adjustments will be influenced by insurer negotiations, generic competition, and formulary decisions.
Regulatory and Reimbursement Factors
- FDA Status: No current post-approval updates that could significantly influence price, though future biosimilar or generic entries could pressure prices.
- Reimbursement: CMS and private insurers primarily reimburse at negotiated rates, impacting net revenue.
- Patent and Exclusivity: Patent protections extend to 2027, with potential for market exclusivity extensions based on formulation patents.
Investment and R&D Outlook
- Large pharmaceutical companies prioritize bipolar disorder and schizophrenia portfolios.
- R&D efforts include developing new formulations, such as long-acting injectables, to penetrate and extend market share.
- The imminent patent expiration in 2027 suggests potential generic competition could reduce prices substantially post-expiry.
Strategic Considerations
- Innovator companies may employ patent extensions or new indications to delay generics.
- Market penetration could accelerate with expanded approved indications, improving pricing power.
- Entry of biosimilars or generics typically reduces prices by 30-70%, depending on market dynamics.
Key Takeaways
- NDC 70000-0525 (Vraylar) holds a solid position in the competitive atypical antipsychotics market with projected price increases of about 3-4% annually until patent expiry in 2027.
- Current wholesale prices hover around $1,200/month, with reimbursement rates slightly higher.
- Market growth remains steady, driven by increasing prevalence of psychiatric conditions and expanded indications.
- Patent expiration will likely bring significant price erosion, pressuring margins.
- Competitive innovations, including new formulations and indications, will influence future pricing strategies.
FAQs
1. What factors will most impact Vraylar’s future pricing?
Patent expiration, entry of generics, insurer negotiations, and potential new indications.
2. How does Vraylar compare to other atypical antipsychotics regarding price?
It is priced higher than older drugs like risperidone but lower than some newer, branded options, reflecting its market position and clinical profile.
3. What is the likelihood of a generic entering the market before 2027?
Patent challenges or settlement agreements could influence timing. Biosimilar competition is unlikely due to the drug’s formulation type.
4. Are there formulations beyond oral tablets that could affect prices?
Yes, long-acting injectable formulations are in development and can command premium pricing but may also produce downward pressure through competition.
5. How will reimbursement trends influence net revenue?
Reimbursement negotiations tend to favor cost-containment, potentially reducing net revenue if discounts and formularies restrict access.
References
[1] Grand View Research. (2022). Antipsychotics Market Size & Trends. https://www.grandviewresearch.com/industry-analysis/antipsychotics-market
